Botanix Pharmaceuticals Email Format
Pharmaceutical ManufacturingWestern Australia, Australia51-200 Employees
Botanix Pharmaceuticals Limited is an ASX-listed dermatology-focused pharmaceutical company. It develops and commercializes treatments for common skin diseases and infections, including Sofdra (sofpironium), which received FDA approval in June 2024 for primary axillary hyperhidrosis and launched in the United States in February 2025. Primary axillary hyperhidrosis is a condition characterized by excessive underarm sweating beyond what is needed to regulate body temperature and reportedly affects about 10 million people in the US. The company is based in Phoenix, United States, and lists an address in West Perth, Western Australia. In the dermatology space, Botanix focuses on therapies intended to provide new options for patients with challenging skin conditions. A recent development includes a May 2026 partnership with Piramal Pharma Solutions to support drug substance development.